Yoshio Ohno-Yoshioka

Shinjuku, 1600023, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 91 publications

Clinical Value of a Novel Apparent Diffusion Coefficient-Based Bi-Color Map for Detecting Clinically Significant Prostate Cancer: A Retrospective Study.

Clinical Value of a Novel Apparent Diffusion Coefficient-Based Bi-Color Map for Detecting Clinically Significant Prostate Cancer: A Retrospective Study.

Journal: Cancers

Published: May 07, 2026

Urinary microRNAs as Prognostic Biomarkers for Predicting the Efficacy of Immune Checkpoint Inhibitors in Patients with Urothelial Carcinoma.

Urinary microRNAs as Prognostic Biomarkers for Predicting the Efficacy of Immune Checkpoint Inhibitors in Patients with Urothelial Carcinoma.

Journal: Cancers

Published: June 24, 2025

Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate Cancer.

Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate Cancer.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: May 21, 2025

Prognostic Impact of Initial Prostate-Specific Antigen in Metastatic Hormone-Sensitive Prostate Cancer Patients With Extensive Bone Metastases Under Androgen Receptor Signaling Inhibitor.

Prognostic Impact of Initial Prostate-Specific Antigen in Metastatic Hormone-Sensitive Prostate Cancer Patients With Extensive Bone Metastases Under Androgen Receptor Signaling Inhibitor.

Journal: The Prostate

Published: May 06, 2025

Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumab.

Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumab.

Journal: International journal of clinical oncology

Published: April 15, 2025

Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab.

Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab.

Journal: Translational andrology and urology

Published: April 04, 2025

Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative Study.

Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: April 02, 2025

Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy.

Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy.

Journal: Scientific reports

Published: February 27, 2025

Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin.

Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin.

Journal: In vivo (Athens, Greece)

Published: January 29, 2025

Rash and Endocrine Disorders Predict Improved Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy.

Rash and Endocrine Disorders Predict Improved Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy.

Journal: Anticancer research

Published: January 26, 2025

Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score's impact.

Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score's impact.

Journal: World journal of urology

Published: December 30, 2024

Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium.

Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium.

Journal: International journal of clinical oncology

Published: November 10, 2024

Showing 1-12 of 91

Last Updated: 09/26/2026